Roth MKM lowered the firm’s price target on Curaleaf (CURLF) to $5 from $7 but keeps a Buy rating on the shares. The company reported a modest decrease in Q3 top-line growth but improved margins, as international revenue and operational emphasis inflects higher, the analyst tells investors in a research note. The firm adds however that attaining its EBITDA target will be dependent on international ramping, with improved 2025 utilization expected to drive margin improvement.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CURLF:
- Curaleaf price target lowered to C$7.25 from C$8.50 at Canaccord
- Curaleaf downgraded to Market Perform from Speculative Buy at Cormark
- Curaleaf price target lowered to C$6.50 from C$11 at Alliance Global Partners
- Curaleaf Holdings Reports Q3 2024 Results
- Curaleaf Holdings Reports Steady Growth Amid Challenges